IP Library Granted Patent US 7,786,070
Granted Patent B2
US 7,786,070 · App. 10/283,751 · Granted Aug 31, 2010

Subcutaneous administration of coagulation factor VII

Assignee: Novo Nordisk HealthCare A/G
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,786,070
App. No.
10/283,751
Granted
Aug 31, 2010
Kind
B2
Abstract

The invention relates to the use of a Factor VIIa for the manufacture of a medicament for treatment of a condition affectable by Factor VIIa, said medicament being for subcutaneous, intramuscular or intradermal administration, and to the use of a Factor VIIa for the manufacture of a medicament for treatment of a condition affectable by Factor VIIa, wherein said medicament, when administered subcutaneously, intradermally or intramuscularly, shows a prolonged biological half-life.

Claims (8)

1. A method for treatment of a condition affectable by Factor VIIa (FVIIa), said method comprising administering subcutaneously to a mammal in need of such treatment an effective amount for treating said condition of a composition comprising modified FVIIa, wherein said modified FVIIa has substantially the same or better biological activity for blood coagulation as authentic FVIIa.

2. The method of claim 1 , wherein the condition is bleeding caused by a lack of, or defect in, coagulation factors VIII, IX, or VII, or by the presence of inhibitors against coagulation factors VIII, IX, or VII.

3. The method of claim 1 , wherein the condition is haemophilia A or B.

4. The method of claim 1 , wherein the modified FVIIa is modified recombinant human FVIIa.

5. The method of claim 1 , wherein the composition is a stable aqueous solution ready for administration.

6. The method of claim 1 , wherein the composition is lyophilized and reconstituted with a pharmaceutically acceptable vehicle suitable for injection prior to administration.

7. The method of claim 1 , wherein the composition is a stable aqueous solution ready for administration.

8. The method of claim 1 , wherein the modified FVII is selected from the group consisting of: [S52A]-FVIIa, [S60A]-FVIIa; Factor VIIa that has been proteolytically cleaved between residues 290 and 291; Factor VIIa that has been proteolytically cleaved between residues 315 and 316; [L305V]-FVIIa; [L305V/M306D/D309S]-FVIIa; [L305I]-FVIIa,[L305T]-FVIIa; [F374P]-FVIIa; [V158T/M298Q]-FVIIal; [V158D/E296V/M298Q]-FVIIa and [K337A]-FVIIa.

Assignments (3)
CHANGE OF ADDRESS Recorded Jun 19, 2013
From: NOVO NORDISK HEALTHCARE A/G
To: NOVO NORDISK HEALTHCARE AG
Reel/Frame 030653/0226 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 14, 2005
From: NOVO NORDISK A/S
To: NOVO NORDISK HEALTHCARE A/G
Reel/Frame 015709/0137 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 21, 2003
From: JOHANNESSEN, MARIE; NORDFANG, OLE JUUL; JANSEN, JENS AAS
To: NOVO NORDISK A/S
Reel/Frame 013680/0020 →
Priority Claims (1)
DK 2001 00477 · Mar 22, 2001 · national
Continuity (3)
Continuation PCTDK010030200 · May 2, 2001
Continuation In Part 1002603200 · Oct 25, 2001
Related Publication 20080145914A1 · Jun 19, 2008